Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"—offering insights into a company's pipeline potential...
On the evening of 30 March, Fosun International announced its 2025 annual results. During the Reporting Period, the Group’s total revenue reached RMB173.43 billion,...
China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers....
Over the past two years, Shoucheng Holdings (0697.HK) has persistently faced a major valuation overhang in the capital markets, namely the supply-side pressure created...
Achieves #1 ranking twice in past three years
S CUBE Capital’s Fixed Income Tactical Opportunities Fund II, managed by the Singapore-based investment manager specializing in...
